CME Presentations
HoFH
Presentations
Addressing Challenges in the Management of HoFH by Listening to Patients
Speakers: Jorge Plutzky, MD, Director, Preventive CardiologyChristie M. Ballantyne, MD, Chief of Cardiology Duration: 60 minutes
Presented on: September 1, 2022
Speakers
Jorge Plutzky, MD
Jorge Plutzky, MD
Director, Preventive Cardiology
Jorge Plutzky, MD, is Director of the Vascular Disease Prevention Program and Director of Preventive Cardiology at Brigham and Women’s Hospital. Dr. Plutzky is an internationally recognized expert in preventive cardiology and lipid disorders, known for his role in helping understand and approach links between cardiovascular disease and metabolic problems like obesity, dyslipidemia, and diabetes. His clinical interests involve lipid/cholesterol issues, improving delivery of preventive therapies using remote management and collaborative teams, and identifying cardiovascular risk in populations like those with rheumatoid disorders and HIV. Furthermore, Dr. Plutzky directs an NIH-funded basic science laboratory that studies transcriptional mechanisms underlying cardio-metabolic disorders.Christie M. Ballantyne, MD
Christie M. Ballantyne, MD
Chief of Cardiology
Christie Ballantyne, MD, is an internationally renowned expert on lipids, atherosclerosis, and heart disease prevention. Dr. Ballantyne is the Chief of Cardiology and the Chief of Cardiovascular Research at Baylor College of Medicine as well as the Director for Cardiometabolic Disease Prevention. His research in biomarkers has led to the FDA approval of 2 biomarkers for risk prediction of CV, and he has played a prominent role in the development and FDA approval of new therapies for treatment of lipids. Due to his research interest in heart disease prevention, Dr. Ballantyne has become an established investigator for the AHA and receives continuous funding from the NIH in research of leukocyte-endothelial interactions, translational research in biomarkers and clinical trials since 1988.
CME Information
Addressing Challenges in the Management of HoFH by Listening to PatientsThis activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC, in collaboration with the National Infusion Center of America (NICA).ACKNOWLEDGEMENT
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.LIVE DATE OF RELEASE
Thursday, September 1, 2022, from 1:30-2:30pm ET.TARGET AUDIENCE
The target audiences for the HCP activity are lipidologists, cardiologists, endocrinologists, and primary care physiciansSTATEMENT OF NEED/PROGRAM OVERVIEW
Patients with homozygous familial hypercholesterolemia (HoFH) are at very high risk for atherosclerotic cardiovascular disease (ASCVD). Early diagnosis, genetic testing, and therapeutic selection are key to achieving lipid-reduction goals. However, patient-specific barriers, combined with other systemic healthcare barriers, hinder the identification of probable cases, limit screening, and delay treatment initiation.
To help overcome these barriers, join a panel of expert cardiologists to review the signs, exam findings, and family histories that suggest the presence of HoFH. Real patient stories will help illustrate the frustrations and obstacles patients face on the way to a diagnosis of HoFH. Expert panelists will then share strategies and tools to enhance patient access to infused medications, apply current guidelines, and identify those patients who can most benefit from newer approved and investigational agents that promise to reduce LDL-C and other lipid particles in patients with HoFH.EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:- Combine clinical history, exam findings, family history, and LDL-C levels to diagnose HoFH earlier
- Develop strategies to address patient barriers and attitudes related to the diagnosis and management of HoFH
- Identify the place of newer agents with novel mechanisms of action in the management of HoFH, while reducing the need for apheresis in adults and children
- Demonstrate an ability to educate patients on strategies to enhance access to infused therapies for HoFH, including referrals and locating an infusion center
PHYSICIAN ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.PHYSICIAN CREDIT DESIGNATION
Global Education Group designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.ESTIMATED TIME TO COMPLETE
This activity should take approximately 60 minutes to complete.INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.FEE INFORMATION & REFUND/CANCELLATION POLICY
There is no fee for this educational activity.DISCLOSURE OF CONFLICTS OF INTEREST
Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:Name of Faculty or Presenter Reported Financial Relationship Christie M. Ballantyne, MD, FACP, FACC
Chief, Section of Cardiology
Chief, Section of Cardiovascular Research
Professor of Medicine
Baylor College of MedicineGrant/Research Support- All significant. (All paid to institution, not individual): Abbott Diagnostic, Akcea, Amgen, Arrowhead, Esperion, Ionis, Merck, Novartis, Novo Nordisk, Regeneron, Roche Diagnostic
Consulting Fee (e.g., Advisory Board - 89Bio, Abbott Diagnostics, Alnylam Pharmaceuticals, Althera, Amarin, Amgen, Arrowhead, Astra Zeneca, Denka Seiken, Esperion, Genentech, Gilead, Illumina, Matinas BioPharma Inc, Merck, New Amsterdam, Novartis, Novo Nordisk, Pfizer, Regeneron, Roche Diagnostic, Sanofi-SynthelaboJorge Plutzky M.D.
Director, Preventive Cardiology
Brigham and Women's HospitalConsulting Fee (e.g., Advisory Board): Alnylam Altimmune, Amgen, Esperion (Clinical trial steering committee), Merck, MJ Health Lifesciences, Novo Nordisk
Contracted Research: Boehringer Ingelheim Novo NordiskChelsea Reimer
Patient PanelistNothing to disclose
The planners and managers have the following relevant financial relationships with ineligible companies:
Name of Planner Reported Financial Relationship Lindsay Borvansky Nothing to disclose Andrea Funk Nothing to disclose Liddy Knight Nothing to disclose Ashley Cann Nothing to disclose Lauren Sinclair Nothing to disclose Carole Drexel Nothing to disclose Colleen Hefner Nothing to disclose Caroline Laurendeau Nothing to disclose Valerie Harrell-Patient Participant Nothing to disclose DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.DISCLAIMER:
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.CONTACT INFORMATION
Accreditation Support:
For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.comTechnical Support:
For any technical issues or issues with your CME Certificate, please contact CardioCareLive at 877-394-1306 or at Support@CardioCareLive.com .Homozygous Familial Hypercholesterolemia: A Call to Action to Improve Diagnosis and Management
LEARNING OBJECTIVES
After completing this activity, the participant should be better able to:- Recognize the signs and symptoms of HoFH based on examination findings, low-density lipoprotein cholesterol (LDL-C) levels, and information from clinical and family histories
- Apply current guidelines for the management of HoFH, in terms of LDL-C targets and therapeutic approaches to LDL-C reduction
- Explain how, when added to conventional therapies, investigational agents with novel mechanisms of action or formulations can help reach LDL-C target goals and reduce non-LDL particles, while reducing the need for apheresis in adults and children
Jointly provided by Postgraduate Institute for Medicine and PlatformQ Health Education, LLC working in collaboration with the American Society for Preventive Cardiology (ASPC), and the Familial Hypercholesterolemia (FH) Foundation.ACKNOWLEDGEMENT
Supported by an educational grant from Novartis and Regeneron.TUITION
Complimentary
JOINT ACCREDITATION STATEMENT
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and PlatformQ Health Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.LIVE CREDIT DESIGNATION STATEMENT
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.ENDURING CREDIT DESIGNATION STATEMENT
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.DATE OF RELEASE/EXPIRATION
Live Activity
Tuesday, July 20, 2021 at 2:00-3:00pm ESTEnduring Material
July 20, 2021 – July 20, 2022.TARGET AUDIENCE
The intended audience for this activity program are cardiologists, PCPs, lipidologists, and endocrinologists.ESTIMATED TIME TO COMPLETE
This activity should take approximately 1 hour to complete.METHOD OF PARTICIPATION
There are no fees to participate in this activity. To participate in the activity, go to www.CardioCareLive.com. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test.HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Faculty or Presenter Reported Financial Relationship Peter P. Toth, MD, PhD, FCCP, FASPC, FAHA, FESC, FACC
Director of Preventative Cardiology
CGH Medical Center
Sterling, Illinois
Professor of Clinical Family and Community Medicine
University of Illinois College of Medicine
Peoria, Illinois
Professor of Clinical Medicine
Michigan State University College of Osteopathic Medicine
East Lansing, Michigan
Adjunct Associate Professor Medicine
Johns Hopkins University School of Medicine
Baltimore, Maryland
President, American Society for Preventive CardiologyConsulting Fees (e.g advisory boards): Amarin, bio89, Kowa, Novartis, and Theravance
Fees for Non-CE Services Received Directly from an Ineligible Entity or their Agents (e.g speakers’ bureaus): Amgen, Esperion, Mereck, Novo-NordiskDeepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC, FACP, FCCP
Harvard Medical School
Executive Director
Interventional Cardiovascular Programs
Brigham and Women's Hospital Heart and Vascular Center
Boston, MAContracted Research: Abbott, Afimmune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Cardax, CellProthera, Cereno Scientific, Chiesi, CSL Behring, Eisai, Ethicon, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Garmin, HLS Therapeutics, Idorsia, Ironwood, Ischemix, Janssen, Lexicon, Lilly, Medtronic, MyoKardia, NirvaMed, Novartis, Novo Nordisk, Owkin, Pfizer, PhaseBio, PLx Pharma, Regeneron, Roche, Sanofi, Synaptic, The Medicines Company, and 89Bio
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Faculty or Presenter Reported Financial Relationship Carole Drexel
Medical Director
PlatformQ Health Education, LLCNone
The PIM planners and managers have nothing to disclose.
The following PlatformQ Health Education, LLC planner, Bridget Griffin, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.DISCLOSURE OF UNAPPROVED/OFF LABEL USE (if applicable):
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.DISCLAIMER:
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.CONTACT INFORMATION
Accreditation Support: Please contact the Postgraduate Institute for Medicine at inquiries@pimed.com.
Technical Support: For any technical issues or issues with your CME Certificate, please contact CardioCareLive at 877-394-1306 or at Support@CardioCareLive.com.